Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-01
2009-06-30
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S398000, C514S401000, C548S311100, C548S326500
Reexamination Certificate
active
07553862
ABSTRACT:
The present invention relates to compounds of formula IwhereinR1, R2,R3, andR4are as defined hereinand to pharmaceutically acceptable acid addition salts thereof. Compounds of formula I or their tautomeric forms are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. Such compounds are useful for the treatment of schizophrenia.
REFERENCES:
patent: WO 2005/040166 (2005-05-01), None
CAPLUS Accession No. 1964:469124, abstract of Bala et al, “5,6-Dimethylbenzimidazole, synthetic precursor in the microbiological production of vitamin B12,” Pharmazie (1964).
Lewis D.A. & Lieberman J.A., Neuron. vol. 28, pp. 325-334 (2000).
Vandenberg R. J. & Aubrey K. R., Exp. Opin. Ther. Targets vol. 5(4) pp. 507-518 (2001).
Nakazato A. & Okuyama S., Exp. Opin. Ther. Patents vol. 10(1) pp. 75-98 (2000).
Sharma T., Br. J. Psychiatry, vol. 174 (Suppl. 38) pp. 44-51 (1999).
Javitt D. C. et al., Biol. Psychiatry, vol. 45 pp. 668-679 (1999).
Mohn A. R. et al., Cell, vol. 98, pp. 427-436 (1999).
Bliss, T. V. & Collingridge G. L., Nature, vol. 361 pp. 31-39 (1993).
Tang J. P. et al., Nature, vol. 401, pp. 63-69 (1999).
Gainetdinov R. R. et al., Trends in Pharm. Sci. vol. 23(8) pp. 367-373 (2002).
Lopez-Corcuera B, et al., Mol. Mem. Biol. vol. 18 pp. 13-20 (2001).
Bergeron R. et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 15730-15734 (1998).
Chen et al., J. Neurophysiol. vol. 89(2) pp. 691-703 (2003).
Armer R. E. & Miller D. J., Exp. Opin. Ther. Patents vol. 11(4) pp. 563-572 (2001).
Pralong E. et al., Prog. in Neurobiol. vol. 67, pp. 173-202 (2002).
Carlsson M. L., J. Neural Trans. vol. 105, pp. 525-535 (1998).
Liebigs, Ann. Chem. 80: pp. 80-82 (1963) (English language translation attached).
Chem. Ber. vol. 97: 2276 (1964).
Chemical Abstract XP002435251.
Chemical Abstract XP002435252.
Chemical Abstract XP002436293.
Jolidon Synese
Narquizian Robert
Norcross Roger
Pinard Emmanuel
Coppins Janet L
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105593